Clinical trials
Mutation clinical trials
Below are recruiting mutation clinical trials, each written for real people, not researchers. We’re tracking 742 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06383728RecruitingPhase 2
Targeted therapy before surgery for EGFR-mutated lung cancer
This trial tests if taking a targeted therapy drug before surgery can help shrink tumors in people with a specific type of lung cancer called EGFR-mutated squamous cell carcinoma that can be removed with surgery. The goal is to see if this approach improves outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06385925RecruitingPhase 1/Phase 2
Study of TSN1611 for cancers with KRAS G12D mutation
This trial tests a new drug called TSN1611 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or stop them from growing.
Houston, TexasAges 18–75 - NCT06386146RecruitingPhase 1/Phase 2
New pill for advanced cancers with TP53 Y220C mutation
This trial tests a new pill called JAB-30355 for people with advanced cancers that have a specific genetic change (TP53 Y220C). It's for those who have already tried other treatments and are looking for a new option.
Denver, ColoradoAges 18 years+ - NCT06387069RecruitingPhase 3
Study of HMPL-306 for AML with IDH1 or IDH2 mutations
This trial tests a new drug called HMPL-306 in people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. It is for patients whose leukemia cells have a specific change in the IDH1 or IDH2 gene.
Hefei, AnhuiAges 18 years+ - NCT06393894Recruiting
Latvian Early Atherosclerosis Registry Study
This study is gathering information from people with early heart artery blockages (occurring before age 55 for men or 65 for women) who need or have had treatment like stents or bypass. It helps doctors understand long-term outcomes.
RigaAges 18–65 - NCT06417814RecruitingPhase 3
Study of Dato-DXd with or without osimertinib for EGFR-mutated lung cancer
This trial tests a new drug, Dato-DXd, given alone or with osimertinib, versus standard chemotherapy for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that has worsened after osimertinib treatment.
Fayetteville, ArkansasAges 18–130 - NCT06430502Recruiting
Cancer vaccine plus immunotherapy for advanced solid tumors
This trial tests a cancer vaccine (called TTV) combined with a PD-1 inhibitor (a type of immunotherapy) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this new combination helps shrink tumors or slow cancer growth.
Wuxi, JiangsuAges 18–85 - NCT06435000Recruiting
A study tracking Stargardt disease progression
This study follows people with Stargardt disease (a genetic eye condition that causes vision loss) over time. It aims to learn more about how the disease progresses and does not test any treatment.
San Diego, CaliforniaAges 12–65 - NCT06440135RecruitingPhase 1
Ziftomenib maintenance after stem cell transplant for AML
This trial tests if the drug ziftomenib can help prevent AML from coming back after a stem cell transplant. It is for people who have certain gene changes (KMT2A rearrangement or NPM1 mutation) and are in remission or near-remission before transplant.
Boston, MassachusettsAges 18 years+ - NCT06440850RecruitingPhase 2
Targeted therapy for high-risk BRAF-mutated thyroid cancer
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
Duarte, CaliforniaAges 18 years+ - NCT06458374Recruiting
Heart Amyloidosis in Carpal Tunnel Surgery Patients
This study looks for people who had carpal tunnel surgery at Ålesund Hospital to check for a rare heart condition called ATTR amyloidosis. It aims to find the disease early and see how common it is.
Ålesund, Møre og RomsdalAges 50 years+ - NCT06462547RecruitingPhase 2
Long-term safety study of INZ-701
This long-term safety study looks at the drug INZ-701 for people with two rare conditions called ENPP1 and ABCC6 deficiencies. If you already took part in an earlier study of this drug, this trial will monitor you over a longer period to see how safe and well it works over time.
Rochester, MinnesotaAges 1 year+ - NCT06465953RecruitingPhase 3
Ivosidenib vs azacitidine for IDH1-mutated MDS
This trial tests if the drug ivosidenib alone or azacitidine alone can help people with a specific type of MDS that has an IDH1 mutation. It is for people who have not had strong MDS treatments yet.
Denver, ColoradoAges 18 years+ - NCT06478251RecruitingPhase 1
Engineered immune cells for KRAS-mutated advanced solid tumors
This trial tests a new type of cell therapy that uses your own immune cells, specially trained to attack cancer cells with a KRAS G12V or G12D mutation. It may be an option if you have advanced solid tumors that no longer respond to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT06481566Recruiting
Almonertinib plus radiation for EGFR-mutant lung cancer
This trial tests combining a targeted pill (almonertinib) with precise radiation to the lung for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than the pill alone.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06484556RecruitingPhase 1
T cell therapy for KRAS-mutated advanced solid tumors
This trial tests a personalized T cell therapy designed to target cancer cells with specific KRAS mutations (G12V or G12D). It may be an option for people with advanced solid tumors who have exhausted standard treatments.
Wuhan, HubeiAges 18–75 - NCT06484790RecruitingPhase 1
Engineered T cell therapy for KRAS-mutated advanced solid tumors
This trial tests a personalized T cell therapy designed to target specific KRAS mutations (G12V or G12D) in people with advanced solid tumors who have no standard treatment options left. The treatment involves collecting your own immune cells, engineering them to recognize and attack cancer cells with these mutations, and then infusing them back into you.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07691827Recruiting
Study of sperm problems linked to inherited genetic mutation
This study is investigating a specific genetic mutation in the MT-ND1 gene that can be passed from mother to son and may cause sperm production problems. It compares men with severe sperm issues to those with normal sperm production to understand the genetic cause.
Guangzhou, GuangdongAges Any age - NCT07155187RecruitingPhase 2/Phase 3
Study of telisotuzumab adizutecan for EGFR-mutated lung cancer
This trial tests a new drug, telisotuzumab adizutecan (given through a vein), alone or with another targeted therapy, versus standard treatments for people with a specific type of advanced lung cancer that has an EGFR mutation and has gotten worse after previous treatment.
Springdale, ArkansasAges 18 years+ - NCT04613596RecruitingPhase 2/Phase 3
Adagrasib for KRAS G12C lung cancer, alone or with pembrolizumab
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
Goodyear, ArizonaAges 18 years+ - NCT06486142RecruitingPhase 3
Comparing targeted pills for EGFR-mutated lung cancer
This study tests three different targeted pills (osimertinib, afatinib, dacomitinib) in people with advanced EGFR-mutated lung cancer who haven't had targeted therapy before. The goal is to find which pill works best and has the fewest side effects.
LundAges 18 years+ - NCT06487377RecruitingPhase 1
IX001 TCR-T for advanced KRAS-mutated pancreatic and colorectal cancer
This trial tests a new treatment called IX001 TCR-T, which uses your own immune cells to target cancer cells with a specific KRAS mutation. It's for people with advanced pancreatic or colorectal cancer who have run out of standard options.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06494358Recruiting
Blood tests to find genetic changes in brain AVM
This trial uses a blood test to look for genetic mutations in brain arteriovenous malformations (bAVMs). It may help doctors understand these lesions better and guide treatment.
ParisAges 18 years+ - NCT06501391RecruitingPhase 2
Brain radiation plus chemo-immunotherapy for untreated NSCLC with stable brain metastases
This trial tests whether combining brain radiation with chemotherapy and immunotherapy can help people with advanced lung cancer that has spread to the brain but has not yet been treated. It is for those whose tumors do not have certain gene mutations (EGFR, ALK, ROS1).
ShanghaiAges 18 years+
Hear when a new Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mutation?
- Yes. Clin2 currently lists 742 recruiting mutation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mutation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mutation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.